Medical Cannabis: Difference between revisions

No edit summary
(Edited the headings.)
 
(7 intermediate revisions by 3 users not shown)
Line 7: Line 7:
== Introduction  ==
== Introduction  ==
[[File:Cannabis oil.jpeg|right|frameless]]
[[File:Cannabis oil.jpeg|right|frameless]]
C. sativa is a flowering, fast growing shrub, commonly known as hemp, cannabis, or marijuana. It originates from Central Asia, and is widely distributed in temperate and tropical areas. For thousands of years, Cannabis sativa has been utilized as a medicine and for recreational and spiritual purposes. Phytocannabinoids are a family of compounds that are found in the cannabis plant, which is known for its psychotogenic and euphoric effects; the main psychotropic constituent of cannabis is THC. The pharmacological effects of cannabinoids are a result of interactions between those compounds and cannabinoid receptors, CB1 and CB2, located in many parts of the human body<ref>Breijyeh,Z.;Jubeh,B.Bufo, S.A.; Karaman, R.; Scrano, L. Cannabis: A Toxin-Producing Plant with Potential Therapeutic Uses.Toxins 2021, 13, 117. Available from: <nowiki>https://res.mdpi.com/d_attachment/toxins/toxins-13-00117/article_deploy/toxins-13-00117.pdf</nowiki>
Cannabis sativa (C. sativa) is a flowering, fast growing shrub, commonly known as hemp, cannabis, or marijuana. It originates from Central Asia, and is widely distributed in temperate and tropical areas. For thousands of years, Cannabis sativa has been utilized as a medicine and for recreational and spiritual purposes.<ref>Maule WJ. Medical uses of marijuana (Cannabis sativa): fact or fallacy?. British journal of biomedical science. 2015 Jan 1;72(2):85-91.</ref> Phytocannabinoids are a family of compounds that are found in some flowering plants (such as cannabis plant), which is known for its psychotogenic and euphoric effects;<ref>Gülck T, Møller BL. Phytocannabinoids: origins and biosynthesis. Trends in Plant Science. 2020 Jul 6.</ref> the main psychotropic constituent of cannabis is Tetrahydrocannabinol (THC).<ref name=":2">PubChem [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004-. PubChem Compound Summary for CID 16078, Dronabinol; [cited 2022 Jan. 29]. Available from: <nowiki>https://pubchem.ncbi.nlm.nih.gov/compound/Dronabinol</nowiki></ref> THC is one of the at least 113 recognized cannabinoids in C. sativa. The pharmacological effects of cannabinoids are a result of interactions between those compounds and cannabinoid receptors, CB1 and CB2, located in many parts of the human body<ref>Breijyeh,Z.;Jubeh,B.Bufo, S.A.; Karaman, R.; Scrano, L. Cannabis: A Toxin-Producing Plant with Potential Therapeutic Uses.Toxins 2021, 13, 117. Available from: <nowiki>https://res.mdpi.com/d_attachment/toxins/toxins-13-00117/article_deploy/toxins-13-00117.pdf</nowiki>


(accessed 5.4.2021)
(accessed 5.4.2021)
Line 13: Line 13:
* Many people around the world believe that the drug should be readily available for both medical and recreational use; however governments around the world still have strict laws about its usage.
* Many people around the world believe that the drug should be readily available for both medical and recreational use; however governments around the world still have strict laws about its usage.
* Each country has its own laws and regulations surrounding the drug; some places are more relaxed, whist others still believe the drug should be an illegal substance<ref>best in Au [https://bestinau.com.au/marijuana-laws-from-around-the-world-where-is-cannabis-legal/ Where is cannabis legal] Available from:https://bestinau.com.au/marijuana-laws-from-around-the-world-where-is-cannabis-legal/ (accessed 5.4.2021)</ref>.
* Each country has its own laws and regulations surrounding the drug; some places are more relaxed, whist others still believe the drug should be an illegal substance<ref>best in Au [https://bestinau.com.au/marijuana-laws-from-around-the-world-where-is-cannabis-legal/ Where is cannabis legal] Available from:https://bestinau.com.au/marijuana-laws-from-around-the-world-where-is-cannabis-legal/ (accessed 5.4.2021)</ref>.
Cannabidiol (CBD), the major non-psychoactive constituent of ''Cannabis sativa'' L., has gained traction as a potential treatment for certain conditions.
Cannabidiol (CBD), the major non-psychoactive constituent of ''Cannabis sativa'' L., has gained popularity as a potential treatment for certain conditions<ref name=":3">Argueta DA, Ventura CM, Kiven S, Sagi V, Gupta K. A balanced approach for cannabidiol use in chronic pain. Frontiers in pharmacology. 2020 Apr 30;11:561.</ref> See below).
== Types of medicinal cannabis products ==
== Types of medicinal cannabis products ==
[[File:Cannabis pills.jpeg|right|frameless|400x400px]]
[[File:Cannabis pills.jpeg|right|frameless|400x400px]]
Cannabis is a complex plant comprising more than 500 constituents, including approximately 100 cannabinoids. The main active ingredients used for medical purposes are tetrahydrocannabinol (THC) and cannabidiol (CBD). THC is the psychoactive part of cannabis that produces a ‘high’, and has been used to treat symptoms such as nausea, pain and muscle spasticity. CBD has no psychoactive properties, and has been used to treat several inflammatory disorders and epilepsy.
Cannabis is a complex plant comprising more than 500 constituents, including approximately 100 cannabinoids. The main active ingredients used for medical purposes are tetrahydrocannabinol (THC) and cannabidiol (CBD). THC is the psychoactive part of cannabis that produces a ‘high’, and has been used to treat symptoms such as nausea, pain and muscle spasticity. CBD has no psychoactive properties, and has been used to treat several inflammatory disorders and epilepsy.<ref name=":3" />


Medicinal cannabis products can come in three main forms:
Medicinal cannabis products can come in three main forms:
# Pharmaceutical: Natural and synthetic medical-grade products with standardised content. The three main products are:
# Pharmaceutical: Natural and synthetic medical-grade products with standardized content. The three main products are:
#* Dronabinol: Synthetic form of THC
#* Dronabinol: Synthetic form of THC<ref name=":2" />
#* Nabilone: Synthetic form of THC
#* Nabilone: Synthetic form of THC
#* Nabiximols: Chemically pure 50:50 mixture of TCH and CBD.
#* Nabiximols: Chemically pure 50:50 mixture of TCH and CBD.
Line 28: Line 28:
== The Evidence ==
== The Evidence ==
[[File:Evidence.jpeg|right|frameless]]
[[File:Evidence.jpeg|right|frameless]]
At present, the evidence base for the use of medicinal cannabis products is limited. The current evidence base for the use of medicinal cannabis products is heterogeneous, comprising a small number of randomised clinical trials when stratified by condition, symptom or intervention type. These studies are of variable quality, including those with high risk of bias (eg incomplete outcome data), low statistical power, and short follow-up time.
At present, the evidence base for the use of medicinal cannabis products is limited.<ref>O’Brien K. Medicinal cannabis: Issues of evidence. European Journal of Integrative Medicine. 2019 Jun 1;28:114-20.</ref> The current evidence base for the use of medicinal cannabis products is heterogeneous, comprising a small number of randomized clinical trials when stratified by condition, symptom or intervention type.<ref>Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV. Cannabinoids for medical use. JAMA [Internet]. 2015; 313 (24): 2456.</ref> <ref name=":0" />These studies are of variable quality, including those with high risk of bias (eg incomplete outcome data), low statistical power, and short follow-up time.
* Recent reviews and analyses indicate there may be some therapeutic benefits of medicinal cannabis products in certain conditions but further research on the treatment efficacy and longer term side effects are warranted.
* Currently, most research and evidence on medicinal cannabis products have come from five clinical conditions: [[Multiple Sclerosis (MS)|multiple sclerosis]]; [[Palliative Care Competence Framework for Physiotherapists|palliative care]]; [[epilepsy]]; nausea and vomiting; and [[Chronic Pain|chronic non-cancer pain]].<ref name=":0" />
* As there is limited scientific evidence to support the use of medicinal cannabis in most conditions, and in many cases the evidence is for its use together with other medicines, it should be used only when approved treatments have been tried and have failed to manage conditions and symptoms.<ref name=":1">Aust Government [https://www.tga.gov.au/publication/guidance-use-medicinal-cannabis-australia-patient-information Guidance on medicinal cannabis] Available from:https://www.tga.gov.au/publication/guidance-use-medicinal-cannabis-australia-patient-information (accessed 5.4.2021)</ref>


Recent reviews and analyses indicate there may be some therapeutic benefits of medicinal cannabis products in certain conditions but further research on the treatment efficacy and longer term side effects are warranted.
=== Chronic Pain ===
The International Association for the Study of Pain (IASP) taskforce looked at all the available research published in peer-reviewed journals on the use of medicinal cannabis for pain management, from preclinical studies to human trials.


Currently, most research and evidence on medicinal cannabis products have come from five clinical conditions: multiple sclerosis; palliative care; epilepsy; nausea and vomiting; and chronic non-cancer pain.<ref name=":0" />
They concluded overall the studies’ “quality, rigour, and transparency of reporting” of benefits and harms needs to be improved across the board. The IASP taskforce demands higher quality data, for example through randomized controlled trials, to determine the safety and efficacy of using medicinal cannabis for pain<ref>IASP Position Statement on the Use of Cannabinoids to Treat Pain Available from:https://www.iasp-pain.org/PublicationsNews/NewsDetail.aspx?ItemNumber=11145&navItemNumber=643 (accessed 5.4.2021)
 
== Chronic Pain ==
The International Association for the Study of Pain taskforce looked at all the available research published in peer-reviewed journals on the use of medicinal cannabis for pain management, from preclinical studies to human trials.
 
They concluded overall the studies’ “quality, rigour, and transparency of reporting” of benefits and harms needs to be improved across the board. We would require higher quality data, for example through randomised controlled trials, to determine the safety and efficacy of using medicinal cannabis for pain<ref>IASP Position Statement on the Use of Cannabinoids to Treat Pain Available from:https://www.iasp-pain.org/PublicationsNews/NewsDetail.aspx?ItemNumber=11145&navItemNumber=643 (accessed 5.4.2021)
</ref>
</ref>


== Multiple sclerosis ==
=== Multiple sclerosis ===
Around half the studies in a recent systematic reviews found that medicinal cannabis products may be effective for pain, spasticity, sleep and bladder function; the others were inconclusive.
Anout 50% of the studies in a recent systematic reviews showed that medicinal cannabis products may be effective for pain, spasticity, sleep and bladder function. The other half had inconclusive results.<ref name=":0" />


== Epilepsy ==
=== Epilepsy ===
A number of studies have found low evidence for the use of medicinal cannabis products for the treatment of paediatric epilepsy, and for patients up to aged 25 years, especially when first-line treatments (ie anti-epileptic drugs) have been found to be ineffective. The numbers needed to treat are as follows:
A number of studies have found low evidence for the use of medicinal cannabis products for the treatment of paediatric epilepsy, and for patients up to aged 25 years, especially when first-line treatments (ie anti-epileptic drugs) have been found to be ineffective. The numbers needed to treat are as follows:
* 50% or greater reduction in seizure frequency: 8
* 50% or greater reduction in seizure frequency: 8
* Complete seizure freedom: 17
* Complete seizure freedom: 17
* Improvement in parental-reported quality of life: 5
* Improvement in parental-reported [[Quality of Life|quality of life]]: 5
* The numbers needed to harm for any adverse event was 3, and serious adverse event was 23.
* The numbers needed to harm for any adverse event was 3, and serious adverse event was 23.


== Palliative care ==
=== Palliative care ===
The use of medicinal cannabis products in palliative care is currently unclear.
The use of medicinal cannabis products in palliative care is currently unclear.
[[File:Pain stress brain.png|right|frameless]]


== Nausea and vomiting ==
=== Nausea and vomiting ===
A small number of studies have found relief of nausea and vomiting in patients with cancer who are undergoing chemotherapy; however, the evidence is lacking and some were compared with now out-of-date practices.
A small number of studies have found relief of nausea and vomiting in patients with [[Oncology|cancer]] who are undergoing [[Chemotherapy Side Effects and Syndromes|chemotherapy]]; however, the evidence is lacking and some were compared with now out-of-date practices.
 
== Chronic non-cancer pain ==
There is some evidence available for the treatment of neuropathic pain using medicinal cannabis products; however, the magnitude of effect is small.10 One systematic review found that the numbers needed to treat was 22 for a 30% reduction and 26 for a 50% reduction in self-reported pain intensity<ref name=":0" /><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u>
== Relevance to Physical Therapy Rehabilitation    ==
 
<br>Since medical and recreational marijuana is becoming legalized in a greater number of states, there is an increased likelihood that physical therapists will treat patients using marijuana to combat different musculoskeletal and neurological conditions. Drug prescription does not fall under the scope of physical therapy practice; therefore, the major role of the therapist is to be an educational resource for patients with questions about the use of medical marijuana. It is recommended that therapists explain the benefits and drawbacks of medical marijuana rather than directly suggesting that the patient initiate using the substance. <ref name="p1">Ciccone CD. Medical Marijuana: Just the Beginning of a Long, Strange Trip? Physical Therapy. 2016;97(2):239–48.</ref><br>
 
Patients may not be well educated on the different routes of administration of marijuana and its extracts. Below is a chart of different marijuana based products with their associated effect times. <br>
 
[[Image:Cannabinoid Administration route .jpg]]
 
Patients who are known users of medicinal or recreational marijuana for analgesic purposes should be encouraged to keep a pain journal.Therapists should have patients periodically complete valid and reliable pain scales to ensure that the treatment is providing the desirable effects. One of the major roles of the physical therapist is to monitor patients for potential abuse of the substance and/or co-administration with alcohol, benzodiazepines, or opioids. These patients may present with amplified confusion or somnolence and demonstrate personality changes or psychotic-like behaviors. If these signs are noted, the problem should be reports the prescribing physician by the therapist. <ref name="p1" /><br>
 
In the table below are several presecribed cannabinoid based medications that have been either been approved by the FDA or are currently under clinical trials. These drugs may start to be prescribed more in the future. <br>
 
[[Image:Prescription Cannabinoid Products .jpg]]<br>
 
Therapists should also be able to identify patients for Cannabis Use Disorder (CUD). (See diagnostic criteria questionnaire below) Patients using marijuana for the use of chronic pain are less likely to suffer from cannabis use problems compared with individuals who used medical cannabis for other reasons (e.g., anxiety, insomnia, and muscle spasms). <ref name="p4">Cohen NL, Heinz AJ, Ilgen M, Bonn-Miller MO. Pain, cannabis species, and cannabis use disorders. J Stud Alcohol Drugs. 2016; 77:515–520.</ref><br>
 
This has been shown to occur primarily in recreational users and risk of this disorder in individuals using medical marijuana has yet to be fully established. <ref name="p5">Richter L, Pugh BS, Ball SA. Assessing the risk of marijuana use disorder among adolescents and adults who use marijuana.Am J Drug Alcohol Abuse. 2016;13:1–14.</ref><br>
 
[[Image:Cannabis Use Disorder .jpg]]
 
== Case Reports/ Case Studies:  ==
 
<br>
 
This page will be continually updated in the future.
 
HIV:<br>Woolridge E, Barton S, Samuel J, Osorio J, Dougherty A, Holdcroft A. Cannabis use in HIV for pain and other medical symptoms. J Pain Symptom Manage 2005;29(4):358-67.<br>http://www.ncbi.nlm.nih.gov/pubmed/15857739
 
Multiple Sclerosis:&nbsp;
 
Consroe P, Musty R, Rein J, Tillery W, Pertwee R. The perceived effects of smoked cannabis on patients with multiple sclerosis. European Neurology 1997;38:44-48.<br>http://www.ncbi.nlm.nih.gov/pubmed/9252798
 
Chong MS, Wolff K, Wise K, Tanton C, Winstock A, Silber E. Cannabis use in patients with multiple sclerosis. Mult Scler 2006;12(5):646-51.<br>http://www.ncbi.nlm.nih.gov/pubmed/17086912
 
Spinal Cord Injury:
 
Malec J, Harvey RF, Cayner JJ. Cannabis effect on spasticity in spinal cord injury. Archives of Physical Medicine and Rehabilitation 1982;63:116-118.<br>http://www.ncbi.nlm.nih.gov/pubmed/6978699
 
Crohn's Disease: <br>Lal S, Prasad N, Ryan M, Tangri S, Silverberg MS, Gordon A, Steinhart H. Cannabis use amongst patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2011;23(10):891-6.<br>http://www.ncbi.nlm.nih.gov/pubmed/21795981<br><br>
 
== Resources    ==
 
For information regarding your states cannabis laws: <br>http://norml.org/
 
For information regarding which strains you or your patient's are using:&nbsp;
 
https://www.leafly.com/
 
For information regarding cannabis therapeutics for different conditions including veterans: <br>http://www.safeaccessnow.org/
 
Realm of Caring: Pediatric Epilepsy
 
https://www.theroc.us/


Information on legal issues: Marijuana policy project:  
=== Chronic non-cancer pain ===
There is some evidence available for the treatment of [[Neuropathic Pain|neuropathic pain]] using medicinal cannabis products; however, the magnitude of effect is small. One systematic review found that the numbers needed to treat was 22 for a 30% reduction and 26 for a 50% reduction in self-reported pain intensity<ref name=":0" />
== Side Effects ==
Like all prescription medicines, medicinal cannabis products can have side effects. The extent of effects of these can vary with the type of medicinal cannabis product and between individuals.
* In general, the side effects of CBD-rich products are less than those for high-THC products, but because the required doses for CBD can be quite high in conditions such as pediatric epilepsies, a proportion of patients encounter side-effects with these CBD doses.
* The known side-effects from medicinal cannabis treatment (both CBD and THC) include fatigue and sedation, vertigo, nausea and vomiting, fever, decreased or increased appetite, dry mouth, and diarrhea.
* THC (and products high in THC) have been associated with convulsions, feeling high or feeling dissatisfied, [[depression]], confusion, hallucinations, paranoid delusions, psychosis, and cognitive distortion (having thoughts that are not true)<ref name=":1" />.


https://www.mpp.org/
== Relevance to Physical Therapy ==
Physiotherapists should be able to educate patients on the reported benefits of cannabis (eg chronic pain, MS, spasticity, and chemotherapy-induced nausea and vomiting) as well as potential adverse effects. Also, trends in the medical use of cannabis can be studied in relation to the extant laws of the country of practice to understand what is allowed in a region concerning the use of medicinal cannabis.


Drug policy information:  
== Summary of Evidence by Condition ==
{| class="wikitable"
!Condition
!Products
!Current evidence quality
|-
! colspan="3" |Multiple sclerosis
|-
|Pain
|Dronabinol, THC extracts
|Low to high and inconsistent
|-
|Disability and its progression
|
|None
|-
|Spasticity
|Nabiximols and THC:CBD
|Low and inconsistent
|-
|Bladder function
|
|None
|-
|Ataxia and tremor
|
|None
|-
|Sleep
|
|None
|-
|Quality of life
|Nabiximols and THC:CBD
|Low and inconsistent
|-
! colspan="3" |Epilepsy
|-
| rowspan="4" |To reduce and/or eliminate the number of seizures
|CBD when used in conjunction with anti-epileptic drugs
|Low to very low
|-
|Oral cannabis extracts (OCEs)
|Very low
|-
|CBD:THC
|Very low
|-
|Cannabis sativa
|Very low
|-
| rowspan="5" |Quality of life
|CBD
|Low
|-
|Oral cannabis extracts (OCEs)
|Very low
|-
|CBD:THC
|Very low
|-
|Cannabis sativa
|Very low
|-
|THC
|Very low
|-
! colspan="3" |Palliative care
|-
|Alzheimer's disease
|Dronabinol
|Unclear
|-
| rowspan="3" |Advanced cancer symptom control
|Dronabinol, THC:CBD, THC
|Unclear but some evidence against use
|-
|Cannabis sativa
|Unclear
|-
|Nabilone
|Unclear
|-
! colspan="3" |Nausea and vomiting
|-
| rowspan="7" |
|Dronabinol
|Low to moderate
|-
|Nabilone
|Very low to moderate
|-
|THC
|Low, insufficient evidence
|-
|Levonantradol
|Low to moderate
|-
|THC:CBD
|Insufficient evidence
|-
|Cannabis sativa extract
|Unclear
|-
|Naximols
|Insufficient evidence
|-
! colspan="3" |Chronic non-cancer pain
|-
| rowspan="7" |
|Nabiximols
|Moderate to high
|-
|Dronabinol
|Low to moderate
|-
|Nabilone
|Very low
|-
|Cannabis sativa
|Very low
|-
|THC extract
|Moderate
|-
|THC:CBD extract
|Low to moderate
|-
|Ajulemic acid
|Very low
|}
Nabiximols is a TGA-registered medicine, under the tradename Sativex. It is a standardised extract of cannabis, containing roughly equal amounts of THC and CBD.


http://www.drugpolicy.org/
Dronabinol is a synthetic form of THC.


== References  ==
Nabilone is a cannabinoid synthesised in the laboratory, and has actions similar to THC although its chemical structure is different.


see [[Adding References|adding references tutorial]].  
Ajulemic acid is a cannabinoid synthesised in the laboratory. It is similar to a breakdown product (metabolite) of THC but does not have psychoactive properties.<ref name=":1" />


==References==
<references />  
<references />  


[[Category:Bellarmine_Student_Project]]
[[Category:Bellarmine_Student_Project]]
[[Category:Global Health]]
[[Category:Pharmacology]]
[[Category:Pain]]

Latest revision as of 17:07, 4 February 2022

 

Original Editors -Mark Wojda from Bellarmine University's Pathophysiology of Complex Patient Problems project.

Top Contributors - Ryan Scinta, Lucinda hampton, Elaine Lonnemann, Kim Jackson, Ryan Barry, WikiSysop, Mark Wojda and Joseph Ayotunde Aderonmu   

Introduction[edit | edit source]

Cannabis oil.jpeg

Cannabis sativa (C. sativa) is a flowering, fast growing shrub, commonly known as hemp, cannabis, or marijuana. It originates from Central Asia, and is widely distributed in temperate and tropical areas. For thousands of years, Cannabis sativa has been utilized as a medicine and for recreational and spiritual purposes.[1] Phytocannabinoids are a family of compounds that are found in some flowering plants (such as cannabis plant), which is known for its psychotogenic and euphoric effects;[2] the main psychotropic constituent of cannabis is Tetrahydrocannabinol (THC).[3] THC is one of the at least 113 recognized cannabinoids in C. sativa. The pharmacological effects of cannabinoids are a result of interactions between those compounds and cannabinoid receptors, CB1 and CB2, located in many parts of the human body[4].

  • Many people around the world believe that the drug should be readily available for both medical and recreational use; however governments around the world still have strict laws about its usage.
  • Each country has its own laws and regulations surrounding the drug; some places are more relaxed, whist others still believe the drug should be an illegal substance[5].

Cannabidiol (CBD), the major non-psychoactive constituent of Cannabis sativa L., has gained popularity as a potential treatment for certain conditions[6] See below).

Types of medicinal cannabis products[edit | edit source]

Cannabis pills.jpeg

Cannabis is a complex plant comprising more than 500 constituents, including approximately 100 cannabinoids. The main active ingredients used for medical purposes are tetrahydrocannabinol (THC) and cannabidiol (CBD). THC is the psychoactive part of cannabis that produces a ‘high’, and has been used to treat symptoms such as nausea, pain and muscle spasticity. CBD has no psychoactive properties, and has been used to treat several inflammatory disorders and epilepsy.[6]

Medicinal cannabis products can come in three main forms:

  1. Pharmaceutical: Natural and synthetic medical-grade products with standardized content. The three main products are:
    • Dronabinol: Synthetic form of THC[3]
    • Nabilone: Synthetic form of THC
    • Nabiximols: Chemically pure 50:50 mixture of TCH and CBD.
  2. Medicinal-grade herbal cannabis: Produced and processed in controlled standard conditions to a medical grade, free of adulterants, higher levels of CBD and other cannabinoids, and contains lower levels of THC. This is provided in herbal form, or processed as an oil, balm, capsule or pill.
  3. Herbal cannabis on the illegal market: Potentially unstable THC and CBD, and may contain adulterants.[7]

The Evidence[edit | edit source]

Evidence.jpeg

At present, the evidence base for the use of medicinal cannabis products is limited.[8] The current evidence base for the use of medicinal cannabis products is heterogeneous, comprising a small number of randomized clinical trials when stratified by condition, symptom or intervention type.[9] [7]These studies are of variable quality, including those with high risk of bias (eg incomplete outcome data), low statistical power, and short follow-up time.

  • Recent reviews and analyses indicate there may be some therapeutic benefits of medicinal cannabis products in certain conditions but further research on the treatment efficacy and longer term side effects are warranted.
  • Currently, most research and evidence on medicinal cannabis products have come from five clinical conditions: multiple sclerosis; palliative care; epilepsy; nausea and vomiting; and chronic non-cancer pain.[7]
  • As there is limited scientific evidence to support the use of medicinal cannabis in most conditions, and in many cases the evidence is for its use together with other medicines, it should be used only when approved treatments have been tried and have failed to manage conditions and symptoms.[10]

Chronic Pain[edit | edit source]

The International Association for the Study of Pain (IASP) taskforce looked at all the available research published in peer-reviewed journals on the use of medicinal cannabis for pain management, from preclinical studies to human trials.

They concluded overall the studies’ “quality, rigour, and transparency of reporting” of benefits and harms needs to be improved across the board. The IASP taskforce demands higher quality data, for example through randomized controlled trials, to determine the safety and efficacy of using medicinal cannabis for pain[11]

Multiple sclerosis[edit | edit source]

Anout 50% of the studies in a recent systematic reviews showed that medicinal cannabis products may be effective for pain, spasticity, sleep and bladder function. The other half had inconclusive results.[7]

Epilepsy[edit | edit source]

A number of studies have found low evidence for the use of medicinal cannabis products for the treatment of paediatric epilepsy, and for patients up to aged 25 years, especially when first-line treatments (ie anti-epileptic drugs) have been found to be ineffective. The numbers needed to treat are as follows:

  • 50% or greater reduction in seizure frequency: 8
  • Complete seizure freedom: 17
  • Improvement in parental-reported quality of life: 5
  • The numbers needed to harm for any adverse event was 3, and serious adverse event was 23.

Palliative care[edit | edit source]

The use of medicinal cannabis products in palliative care is currently unclear.

Pain stress brain.png

Nausea and vomiting[edit | edit source]

A small number of studies have found relief of nausea and vomiting in patients with cancer who are undergoing chemotherapy; however, the evidence is lacking and some were compared with now out-of-date practices.

Chronic non-cancer pain[edit | edit source]

There is some evidence available for the treatment of neuropathic pain using medicinal cannabis products; however, the magnitude of effect is small. One systematic review found that the numbers needed to treat was 22 for a 30% reduction and 26 for a 50% reduction in self-reported pain intensity[7]

Side Effects[edit | edit source]

Like all prescription medicines, medicinal cannabis products can have side effects. The extent of effects of these can vary with the type of medicinal cannabis product and between individuals.

  • In general, the side effects of CBD-rich products are less than those for high-THC products, but because the required doses for CBD can be quite high in conditions such as pediatric epilepsies, a proportion of patients encounter side-effects with these CBD doses.
  • The known side-effects from medicinal cannabis treatment (both CBD and THC) include fatigue and sedation, vertigo, nausea and vomiting, fever, decreased or increased appetite, dry mouth, and diarrhea.
  • THC (and products high in THC) have been associated with convulsions, feeling high or feeling dissatisfied, depression, confusion, hallucinations, paranoid delusions, psychosis, and cognitive distortion (having thoughts that are not true)[10].

Relevance to Physical Therapy[edit | edit source]

Physiotherapists should be able to educate patients on the reported benefits of cannabis (eg chronic pain, MS, spasticity, and chemotherapy-induced nausea and vomiting) as well as potential adverse effects. Also, trends in the medical use of cannabis can be studied in relation to the extant laws of the country of practice to understand what is allowed in a region concerning the use of medicinal cannabis.

Summary of Evidence by Condition[edit | edit source]

Condition Products Current evidence quality
Multiple sclerosis
Pain Dronabinol, THC extracts Low to high and inconsistent
Disability and its progression None
Spasticity Nabiximols and THC:CBD Low and inconsistent
Bladder function None
Ataxia and tremor None
Sleep None
Quality of life Nabiximols and THC:CBD Low and inconsistent
Epilepsy
To reduce and/or eliminate the number of seizures CBD when used in conjunction with anti-epileptic drugs Low to very low
Oral cannabis extracts (OCEs) Very low
CBD:THC Very low
Cannabis sativa Very low
Quality of life CBD Low
Oral cannabis extracts (OCEs) Very low
CBD:THC Very low
Cannabis sativa Very low
THC Very low
Palliative care
Alzheimer's disease Dronabinol Unclear
Advanced cancer symptom control Dronabinol, THC:CBD, THC Unclear but some evidence against use
Cannabis sativa Unclear
Nabilone Unclear
Nausea and vomiting
Dronabinol Low to moderate
Nabilone Very low to moderate
THC Low, insufficient evidence
Levonantradol Low to moderate
THC:CBD Insufficient evidence
Cannabis sativa extract Unclear
Naximols Insufficient evidence
Chronic non-cancer pain
Nabiximols Moderate to high
Dronabinol Low to moderate
Nabilone Very low
Cannabis sativa Very low
THC extract Moderate
THC:CBD extract Low to moderate
Ajulemic acid Very low

Nabiximols is a TGA-registered medicine, under the tradename Sativex. It is a standardised extract of cannabis, containing roughly equal amounts of THC and CBD.

Dronabinol is a synthetic form of THC.

Nabilone is a cannabinoid synthesised in the laboratory, and has actions similar to THC although its chemical structure is different.

Ajulemic acid is a cannabinoid synthesised in the laboratory. It is similar to a breakdown product (metabolite) of THC but does not have psychoactive properties.[10]

References[edit | edit source]

  1. ↑ Maule WJ. Medical uses of marijuana (Cannabis sativa): fact or fallacy?. British journal of biomedical science. 2015 Jan 1;72(2):85-91.
  2. ↑ Gülck T, Møller BL. Phytocannabinoids: origins and biosynthesis. Trends in Plant Science. 2020 Jul 6.
  3. ↑ 3.0 3.1 PubChem [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004-. PubChem Compound Summary for CID 16078, Dronabinol; [cited 2022 Jan. 29]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Dronabinol
  4. ↑ Breijyeh,Z.;Jubeh,B.Bufo, S.A.; Karaman, R.; Scrano, L. Cannabis: A Toxin-Producing Plant with Potential Therapeutic Uses.Toxins 2021, 13, 117. Available from: https://res.mdpi.com/d_attachment/toxins/toxins-13-00117/article_deploy/toxins-13-00117.pdf (accessed 5.4.2021)
  5. ↑ best in Au Where is cannabis legal Available from:https://bestinau.com.au/marijuana-laws-from-around-the-world-where-is-cannabis-legal/ (accessed 5.4.2021)
  6. ↑ 6.0 6.1 Argueta DA, Ventura CM, Kiven S, Sagi V, Gupta K. A balanced approach for cannabidiol use in chronic pain. Frontiers in pharmacology. 2020 Apr 30;11:561.
  7. ↑ 7.0 7.1 7.2 7.3 7.4 RACGP Medicinal Cannabis Available from:https://www.racgp.org.au/advocacy/position-statements/view-all-position-statements/clinical-and-practice-management/medical-cannabis (accessed 5.4.2021)
  8. ↑ O’Brien K. Medicinal cannabis: Issues of evidence. European Journal of Integrative Medicine. 2019 Jun 1;28:114-20.
  9. ↑ Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV. Cannabinoids for medical use. JAMA [Internet]. 2015; 313 (24): 2456.
  10. ↑ 10.0 10.1 10.2 Aust Government Guidance on medicinal cannabis Available from:https://www.tga.gov.au/publication/guidance-use-medicinal-cannabis-australia-patient-information (accessed 5.4.2021)
  11. ↑ IASP Position Statement on the Use of Cannabinoids to Treat Pain Available from:https://www.iasp-pain.org/PublicationsNews/NewsDetail.aspx?ItemNumber=11145&navItemNumber=643 (accessed 5.4.2021)
Retrieved from "https://www.physio-pedia.com/index.php?title=Medical_Cannabis&oldid=293333"